Jordan's Hikma to buy Baxter's US generic injectables business
This article was originally published in Scrip
Executive Summary
Hikma Pharmaceuticals is to acquire Baxter's US generic injectables business for $112 million in cash to position it as the second largest injectables supplier in the US.